Homocysteine-induced brain lipid peroxidation: effects of NMDA receptor blockade, antioxidant treatment, and nitric oxide synthase inhibition A Jara-Prado, A Ortega-Vazquez, LM Ruano, C Rios, A Santamaria Neurotoxicity research 5, 237-243, 2003 | 138 | 2003 |
HLA-A*02:01:01/-B*35:01:01/-C*04:01:01 haplotype associated with lamotrigine-induced maculopapular exanthema in Mexican Mestizo patients I Fricke-Galindo, IE Martínez-Juárez, N Monroy-Jaramillo, H Jung-Cook, ... Pharmacogenomics 15 (15), 1881-1891, 2014 | 56 | 2014 |
CYP2D6 ultrarapid metabolism and early dropout from fluoxetine or amitriptyline monotherapy treatment in major depressive patients EM Penas-Lledo, HD Trejo, P Dorado, A Ortega, H Jung, E Alonso, ... Molecular psychiatry 18 (1), 8-9, 2013 | 54 | 2013 |
Interethnic Variability in CYP2D6, CYP2C9, and CYP2C19 Genes and Predicted Drug Metabolism Phenotypes Among 6060 Ibero- and Native Americans: RIBEF … MEG Naranjo, F Rodrigues-Soares, EM Penas-Lledo, E Tarazona-Santos, ... Omics: a journal of integrative biology 22 (9), 575-588, 2018 | 40 | 2018 |
CYP2C9, CYP2C19, ABCB1 genetic polymorphisms and phenytoin plasma concentrations in Mexican-Mestizo patients with epilepsy A Ortega-Vázquez, P Dorado, I Fricke-Galindo, H Jung-Cook, ... The Pharmacogenomics Journal 16 (3), 286-292, 2016 | 36 | 2016 |
Genomic Ancestry, CYP2D6, CYP2C9, and CYP2C19 Among Latin Americans F Rodrigues‐Soares, EM Peñas‐Lledó, E Tarazona‐Santos, ... Clinical Pharmacology & Therapeutics 107 (1), 257-268, 2020 | 31 | 2020 |
Interethnic differences in UGT1A4 genetic polymorphisms between Mexican Mestizo and Spanish populations M López, P Dorado, A Ortega, E Peñas-Lledó, N Monroy, I Silva-Zolezzi, ... Molecular biology reports 40, 3187-3192, 2013 | 29 | 2013 |
Losartan hydroxylation phenotype in an Ecuadorian population: influence of CYP2C9 genetic polymorphism, habits and gender P Dorado, LJ Beltrán, E Machin, EM Penas-LLedo, E Terán, A LLerena, ... Pharmacogenomics 13 (15), 1711-1717, 2012 | 27 | 2012 |
Pharmacogenetics in Central American healthy volunteers: interethnic variability C Céspedes-Garro, MEG Naranjo, R Ramírez, V Serrano, H Fariñas, ... Drug Metabolism and Personalized Therapy 30 (1), 19-31, 2015 | 23 | 2015 |
CYP2D6 -1584C>G promoter polymorphism and debrisoquine ultrarapid hydroxylation in healthy volunteers A LLerena, P Dorado, R Ramírez, LR Calzadilla, E Penas-LLedo, ... Pharmacogenomics 14 (16), 1973-1977, 2013 | 23 | 2013 |
CYP2D6 genetic polymorphisms in Southern Mexican Mayan Lacandones and Mestizos from Chiapas ALL Marisol López-López , Eva Peñas-Lledó, Pedro Dorado, Alberto Ortega ... Pharmacogenomics 15 (15), 1859-1865, 2014 | 21 | 2014 |
Pharmacogenetic potential biomarkers for carbamazepine adverse drug reactions and clinical response NM Jaramillo, IF Galindo, AO Vázquez, HJ Cook, A LLerena, ML López Drug metabolism and drug interactions 29 (2), 67-79, 2014 | 19 | 2014 |
Pharmacogenetic studies in Alzheimer disease TZ Santamaría, PY Gómez, IF Galindo, MG González, AO Vázquez, ... Neurología (English Edition) 37 (4), 287-303, 2022 | 16 | 2022 |
Microsatélites A Vázquez, A Morales Herramientas moleculares aplicadas en ecología: aspectos teóricos y prácticos, 2014 | 14 | 2014 |
Evaluation of drug-metabolizing enzyme hydroxylation phenotypes in Hispanic populations: the CEIBA cocktail F De Andrés, M Sosa-Macías, BP Lazalde-Ramos, MEG Naranjo, ... Drug metabolism and drug interactions 28 (3), 135-146, 2013 | 14 | 2013 |
Genetic variability among Mexican Mestizo and Amerindian populations based on three ABCB1 polymorphisms AF Favela-Mendoza, H Rangel-Villalobos, I Fricke-Galindo, ... Molecular biology reports 45, 2525-2533, 2018 | 12 | 2018 |
Development of a HPLC method for the determination of losartan urinary metabolic ratio to be used for the determination of CYP2C9 hydroxylation phenotypes P Dorado, E Machín, F de Andrés, MEG Naranjo, EM Peñas-Lledó, ... Drug Metabolism and Drug Interactions 27 (4), 217-223, 2012 | 12 | 2012 |
Consortium of the Ibero-American Network of Pharmacogenetics and Pharmacogenomics RIBEF. Pharmacogenetics in Latin American populations: regulatory aspects, application to … I Rodeiro, D Remírez-Figueredo, M García-Mesa, P Dorado, A LLerena, ... Drug Metabol Drug Interact 27 (1), 57-60, 2012 | 11 | 2012 |
Niemann-Pick disease A or B in four pediatric patients and SMPD1 mutation carrier frequency in the Mexican population M Cerón-Rodríguez, ER Vázquez-Martínez, C García-Delgado, ... Annals of Hepatology 18 (4), 613-619, 2019 | 10 | 2019 |
Integrative genomic–epigenomic analysis of clozapine-treated patients with refractory psychosis YG Mayén-Lobo, JJ Martínez-Magaña, BE Pérez-Aldana, ... Pharmaceuticals 14 (2), 118, 2021 | 9 | 2021 |